Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on New Jersey Health Reporter.
Press releases published on August 29, 2025
SRx Health Solutions Cancels an Additional 350,000 Shares, Increasing the Total Number of Shares Canceled to Over 19 Million
GlobeNewswire
·
August 29, 2025
TAMPA, Fla., Aug. 29, 2025 (GLOBE NEWSWIRE) -- SRx Health Solutions, Inc. (NYSE American: SRXH) (the “Company”), a leading global health and wellness company, today announced the cancellation of an additional 350,000 shares, increasing the total number of …
AMALFI Randomized Clinical Trial Results Demonstrate Increased Atrial Fibrillation Diagnosis with Home-Based Long-Term Continuous ECG Monitoring Using iRhythm Technologies’ Zio LTCM Service
GlobeNewswire
·
August 29, 2025
Oxford University-led AMALFI clinical trial results presented at the European Society of Cardiology (ESC) Congress 2025 and published in the Journal of the American Medical Association (JAMA). AMALFI tested whether home-based, self-applied use of iRhythm’s …
Conavi Medical Reports Fiscal Q3 2025 Interim Results and Operational Highlights
GlobeNewswire
·
August 29, 2025
US FDA 510(k) submission remains on track for calendar Q3 2025 Successful validation testing of Novasight Hybrid™ system with key opinion leaders Recent academic publications underscore importance of intravascular imaging and potential of hybrid IVUS / OCT …
Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2025
GlobeNewswire
·
August 29, 2025
PRINCETON, N.J., Aug. 29, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences in September. Cantor Global Healthcare Conference 2025 in …
Arvinas to Participate in Upcoming Investor Conferences
GlobeNewswire
·
August 29, 2025
NEW HAVEN, Conn., Aug. 29, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in fireside chats …
Alumis to Participate in Upcoming September Investor Conferences
GlobeNewswire
·
August 29, 2025
SOUTH SAN FRANCISCO, Calif., Aug. 29, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced that the Company will …
Eledon Pharmaceuticals to Participate in Cantor Global Healthcare Conference 2025
GlobeNewswire
·
August 29, 2025
IRVINE, Calif., Aug. 29, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that David-Alexandre C. Gros, M.D., Chief Executive Officer, will participate in a fireside chat at the upcoming Cantor Global …
Bicycle Toxin Conjugates Clinical Trials FDA Approval Proprietary Technology Cancer Drugs Report 2025
GlobeNewswire
·
August 29, 2025
Delhi, Aug. 29, 2025 (GLOBE NEWSWIRE) -- Global Bicycle Toxin Conjugates Clinical Trials, Proprietary Platforms …
RNA Polymerase I POL 1 Clinical Trials Companies FDA Approval Development Trends Report 2025
GlobeNewswire
·
August 29, 2025
Delhi, Aug. 29, 2025 (GLOBE NEWSWIRE) -- Global RNA Polymerase I Clinical Trials, Development Trends By Indications, Target Approaches …
Tetraspecific Antibodies Clinical Trials FDA Approval Development Technologies Platforms Market Opportunity Companies Report 2025
GlobeNewswire
·
August 29, 2025
Delhi, Aug. 29, 2025 (GLOBE NEWSWIRE) -- Global Tetraspecific Antibodies Clinical Trials, Proprietary Technologies, Therapeutic Approaches …
Bispecific Antibody Drug Conjugates ADC Clinical Trials FDA Approval Companies Commercial Launch Report 2025
GlobeNewswire
·
August 29, 2025
Delhi, Aug. 29, 2025 (GLOBE NEWSWIRE) -- Global Bispecific Antibody Drug Conjugates Clinical Trials, Development Platforms, Competitive Landscape and Market Opportunity Insight 2025 Report Findings and Highlights: First Bispecific Antibody Drug Conjugate …
Controlled Release Drug Delivery Market Size FDA Approved Drugs Clinical Trials Companies Report 2030
GlobeNewswire
·
August 29, 2025
Delhi, Aug. 29, 2025 (GLOBE NEWSWIRE) -- Global Controlled Release Drug Delivery Market, Drug Dosage, Price, Sales and Clinical Trials Insight 2030 Report Finding and Highlights: Research Methodology Followed Global and Regional Market Overview Global …
OSE Immunotherapeutics Reaffirms its Strategic Priorities and Publishes Shareholder Q&A to Restore Information Ahead of AGM
GlobeNewswire
·
August 29, 2025
OSE Immunotherapeutics Reaffirms its Strategic Priorities and Publishes Shareholder Q&A to Restore Information Ahead of AGM Nantes, August 29, 2025, 8:00 a.m. CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today published a comprehensive …
OSE Immunotherapeutics Réaffirme ses Priorités Stratégiques et Publie un Document Questions-Réponses Destiné aux Actionnaires pour Rétablir l’Information Avant l’Assemblée Générale
GlobeNewswire
·
August 29, 2025
OSE Immunotherapeutics Réaffirme ses Priorités Stratégiques et Publie un Document Questions-Réponses Destiné aux Actionnaires pour Rétablir l’Information Avant l’Assemblée Générale NANTES, France - 29 août 2025, 8h00 CET – OSE Immunotherapeutics SA (ISIN: …
Santhera schliesst Vereinbarung mit Ikris Pharma Network über den Vertrieb von AGAMREE® (Vamorolon) in Indien
GlobeNewswire
·
August 29, 2025
Pratteln, Schweiz, 29. August 2025 – Santhera Pharmaceuticals (SIX: SANN) gibt die Unterzeichnung einer exklusiven Vereinbarung mit Ikris Pharma Network (Ikris) über den Vertrieb von AGAMREE® (Vamorolon) in Indien zur Behandlung von Duchenne- …
Santhera Enters into Agreement with Ikris Pharma Network for the Distribution of AGAMREE® (Vamorolone) in India
GlobeNewswire
·
August 29, 2025
Pratteln, Switzerland, 29 August, 2025 – Santhera Pharmaceuticals (SIX: SANN) announces the signing of an exclusive agreement with Ikris Pharma Network (Ikris) to manage the distribution of AGAMREE® (vamorolone) in India, for the treatment of Duchenne …
Banner Year for Mesoblast With First FDA Product Approval and Successful Commercial Launch of Ryoncil®
GlobeNewswire
·
August 29, 2025
NEW YORK, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today provided financial results and an operational update for the period ended June 30, 2025. …